Skip to main content

Chugai Expands Gene Bridges License

NEW YORK (GenomeWeb News) – Gene Bridges said today that the Chugai Pharmaceutical has expanded a license for the company's recombination technology.

The Japanese pharmaceutical firm agreed to expand a commercial license for the Red/ET technology that the companies originally struck in 2005.

Patented in Japan as a "Novel DNA Cloning Method," the Red/ET technology is used for generating targeting vectors or modifying E. coli chromosomes. The methodology allows cloning, subcloning, and DNA modification at any position, Gene Bridges said.

Gene Bridges is a spin-off from the European Molecular Biology Laboratory and is based in Heidelberg, Germany.

Financial terms of the agreement were not released.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.